High Tide (HITI) Q2 2026 earnings review
Acquisition Masks Decelerating Core Growth as E-Commerce is Swept Under the Rug
High Tide posted a massive 30% YoY revenue jump to $179.3M and reached near-breakeven Net Income ($24k). However, the headline growth is a mirage. Almost all the incremental revenue came from the newly acquired German distributor, Remexian ($31.6M), which contributed just $372k in operating profit (1.2% margin). Meanwhile, the legacy Bricks-and-Mortar business decelerated to 7% YoY growth. Management also quietly merged the rapidly shrinking e-commerce division into the retail segment, obscuring its continued collapse. High Tide is trading quality for volume, and the core Canadian retail engine is no longer growing at historical rates, though its profitability is recovering.
🐂 Bull Case
Despite slower top-line growth, the Bricks-and-Mortar segment expanded operating income from $0.9M in 25Q2 to $5.7M in 26Q2. The company is extracting massive operating leverage from its established Canadian footprint.
High Tide successfully reversed its multi-year trend of net losses, achieving $24k in consolidated Net Income this quarter (up from a $2.8M loss a year ago).
🐻 Bear Case
The new Medical Cannabis Distribution segment operates on a razor-thin 1.2% operating margin, drastically altering the company's profitability profile and dragging down consolidated returns on capital.
By merging the failing e-commerce business into the Bricks-and-Mortar segment, management has reduced transparency. U.S. revenues (a proxy for e-commerce) plunged another 30% YoY.
⚖️ Verdict: ⚪
Neutral. The core Canadian retail business is highly profitable and cash-generative, but the pivot toward low-margin European wholesale and the obfuscation of the failing e-commerce segment raise serious concerns about capital allocation and long-term margin trajectory.
Key Themes
E-Commerce Collapse Hidden by Segment Merger
Effective February 1, 2026, High Tide combined its struggling e-commerce segment into its Bricks-and-Mortar segment. This is a classic tactic to hide a declining business. Looking at the geographic breakdown, U.S. revenue (which is entirely e-commerce) is decelerating sharply, falling 30% YoY to $3.2M. While management previously claimed e-commerce was 'strategic' for future U.S. entry, the data suggests it is simply dying.
Remexian Drives Top-Line, Dilutes Margins
The acquisition of Remexian artificially inflated High Tide's growth metrics. While it added $31.6M in quarterly revenue, it generated a paltry $372k in operating income. This 1.2% operating margin severely dilutes the consolidated margin profile and highlights the risk of aggressively buying low-quality wholesale revenue to maintain the illusion of high growth.
Operating Leverage in Canadian Retail
The standout positive is the organic retail business. Bricks-and-Mortar operating income accelerated by over 500% YoY, reaching $5.7M. The company has successfully absorbed the SSSg slowdown by controlling costs and pushing higher-margin White Label products (Queen of Bud, Cabana Cannabis Co.) through its 221-store network.
Disciplined Store Expansion Continues
High Tide grew its Canadian retail footprint to 221 locations, maintaining its status as Canada's largest cannabis retail chain. The strategic pace of self-funded, organic store growth limits the need for expensive M&A in the saturated Canadian market. They expect to hit 228 stores shortly after closing pending acquisitions.
Cabana Club Ecosystem and Data Analytics
The discount club model continues to be the primary engine for SSSg outperformance versus peers. High Tide effectively uses its scale to extract high-margin data analytics and advertising revenue from licensed producers, offsetting the intense price compression seen in physical retail.
Ballooning Derivative Liability
The structure of the Remexian acquisition has created a massive balance sheet risk. High Tide issued a put option for the remaining 49% of Remexian tied to a 3.64x EBITDA multiple. The liability for this option climbed to $57.9M this quarter, forcing the company to record a $1.67M non-cash fair value loss. This creates unpredictable earnings volatility going forward.
German Regulatory Risk Built Into Deal Structure
Management explicitly acknowledges the regulatory risk in the German 'MedCanG' laws. High Tide holds a $1.3M contingent contract asset that protects them if German regulations change and Remexian's EBITDA drops by more than 30%. This highlights the precarious nature of the European regulatory environment.
Other KPIs
Accelerating from $8.9M in the prior year. High Tide's ability to generate structural cash flow from operations allows it to self-fund its ambitious 20-30 store annual expansion target without diluting shareholders heavily.
Stable. The company maintains a healthy liquidity position. Following the quarter's end, they secured a $40M credit facility with BMO at standard commercial rates, which will replace the expensive ConnectFirst credit union loan and free up $7.5M in restricted cash.
Guidance
Stable. The company reiterated its target to open 20-30 locations this calendar year, focusing primarily on organic growth rather than M&A.
Stable. High Tide aims to expand significantly from its current 221-store footprint, indicating confidence in capturing further market share as weaker independent operators exit the Canadian market.
Key Questions
E-Commerce Merger Transparency
You merged the e-commerce segment into Bricks-and-Mortar this quarter, citing resource allocation. Given the 30% drop in U.S. revenues, isn't this masking the structural failure of your e-commerce roll-out strategy?
Remexian Margin Trajectory
Remexian added nearly $32M in revenue but only $372k in operating profit. Is a 1.2% operating margin the normalized expectation for the Medical Cannabis Distribution segment, or are there specific synergies that will expand this margin over the next 12 months?
Put Option Liability
The put option liability for the remaining 49% of Remexian has ballooned to $57.9M. At 3.64x trailing EBITDA, how are you preparing the balance sheet to absorb this potential cash outlay when the option becomes exercisable in September 2027?